Research Analysts Set Expectations for IKT FY2025 Earnings

Inhibikase Therapeutics, Inc. (NYSE:IKT) – Equities researchers at Lifesci Capital issued their FY2025 earnings per share estimates for Inhibikase Therapeutics in a report issued on Monday, February 23rd. Lifesci Capital analyst G. Maini anticipates that the company will post earnings of ($0.57) per share for the year. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.97) per share. Lifesci Capital also issued estimates for Inhibikase Therapeutics’ Q4 2025 earnings at ($0.12) EPS.

Several other analysts also recently weighed in on IKT. Jefferies Financial Group reaffirmed a “buy” rating on shares of Inhibikase Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald began coverage on shares of Inhibikase Therapeutics in a research report on Thursday, December 11th. They issued an “overweight” rating and a $4.00 price objective for the company. Bank of America assumed coverage on Inhibikase Therapeutics in a report on Wednesday, January 21st. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Inhibikase Therapeutics in a research note on Friday, December 26th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Inhibikase Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $6.00.

Inhibikase Therapeutics Stock Performance

Shares of IKT opened at $2.05 on Thursday. The stock has a market capitalization of $154.11 million, a P/E ratio of -0.77 and a beta of 0.84. Inhibikase Therapeutics has a 1 year low of $1.33 and a 1 year high of $2.58. The company’s fifty day moving average is $1.76 and its two-hundred day moving average is $1.66.

Institutional Investors Weigh In On Inhibikase Therapeutics

Institutional investors have recently modified their holdings of the company. Intech Investment Management LLC purchased a new position in Inhibikase Therapeutics in the 2nd quarter valued at approximately $61,000. Geode Capital Management LLC grew its holdings in Inhibikase Therapeutics by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 1,128,239 shares of the company’s stock valued at $2,313,000 after purchasing an additional 15,665 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Inhibikase Therapeutics in the fourth quarter valued at $238,000. Sands Capital Alternatives LLC increased its position in shares of Inhibikase Therapeutics by 18.9% in the fourth quarter. Sands Capital Alternatives LLC now owns 13,018,965 shares of the company’s stock valued at $26,689,000 after buying an additional 2,068,965 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Inhibikase Therapeutics by 48.3% during the 4th quarter. Wells Fargo & Company MN now owns 67,833 shares of the company’s stock worth $139,000 after buying an additional 22,088 shares during the last quarter. Hedge funds and other institutional investors own 3.81% of the company’s stock.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for rare neurodegenerative diseases. Headquartered in New Haven, Connecticut, the company focuses on advancing therapies for central nervous system disorders with high unmet medical need. Its research platform targets key signaling pathways implicated in neuronal survival and degeneration.

The company’s lead investigational candidate, IKT-148009, is a brain-penetrant inhibitor of PDK1 and ABL kinases.